1485529-16-5

Basic information

• Product Name: (E)-ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylate
• Synonyms: (E)-ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylate
• CAS NO: 1485529-16-5
• Molecular Weight: 336.503
• Mol File: 1485529-16-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (E)-ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylate(1485529-16-5)
• EPA Substance Registry System: (E)-ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylate(1485529-16-5)

Safety Data

• Hazardous Substances Data: 1485529-16-5(Hazardous Substances Data)

Upstream product

• 4046-02-0 ethyl 4-hydroxy-3-methoxycinnamate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 121-33-5 vanillin 

Downstream Products

• 1612146-72-1 (E)-4-(3-((2-amino-4,5,6,7-tetrahydrobenzo[d] thiazol-6-yl)(propyl)amino)prop-1-en-1-yl)-2-methoxyphenol 
• 458-36-6 trans-coniferyl aldehyde 
• 290820-47-2 (2E)-3-[4-[[tert-butyldimethylsilyl]oxy]-3-methoxyphenyl]acrylaldehyde 
• 290820-48-3 (E)-3-( 4-( (tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)prop-2-en-1-ol 

Relevant articles and documents

Novel multifunctional dopamine D2/D3receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties

Our ongoing drug development endeavor to design compounds for symptomatic and neuroprotective treatment of Parkinson's disease (PD) led us to carry out a structure activity relationship study based on dopamine agonists pramipexole and 5-OHDPAT. Our goal was to incorporate structural elements in these agonists in a way to preserve their agonist activity while producing inhibitory activity against aggregation of α-synuclein protein. In our design we appended various catechol and related phenol derivatives to the parent agonists via different linker lengths. Structural optimization led to development of several potent agonists among which (?)-8a, (?)-14 and (?)-20 exhibited potent neuroprotective properties in a cellular PD model involving neurotoxin 6-OHDA. The lead compounds (?)-8a and (?)-14 were able to modulate aggregation of α-synuclein protein efficiently. Finally, in an in vivo PD animal model, compound (?)-8a exhibited efficacious anti-parkinsonian effect.